Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone

• Published in: Journal of diabetes and its complications Vol. 38; no. 5; p. 108741
• Main Authors: Filardi, Tiziana, Feraco, Alessandra, Ouvrard-Pascaud, Antoine, Rizzo, Manfredi, Caprio, Massimiliano
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-05-2024; Elsevier Limited
• Subjects: Cardio-renal-metabolic risk; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Chronic kidney disease; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetic kidney disease; Diabetic Nephropathies - epidemiology; Diabetic Nephropathies - therapy; Finerenone; Genotype & phenotype; Glucose; Humans; Hyperkalemia; Kidney diseases; Metabolism; Mineralocorticoid receptor; Mineralocorticoid Receptor Antagonists - therapeutic use; Mortality; Naphthyridines - therapeutic use; Patients; Type 2 diabetes mellitus; Chronic kidney disease; Type 2 diabetes mellitus; Cardio-renal-metabolic risk; Mineralocorticoid receptor; Finerenone; Diabetic kidney disease
• ISSN: 1056-8727; 1873-460X
• DOI: 10.1016/j.jdiacomp.2024.108741

•Diabetic kidney disease (DKD) develops in nearly 40% of patients with diabetes, and is a leading cause of end-stage renal disease (ESRD)•Renin-angiotensin-aldosterone system (RAAS) inhibition still remains the cornerstone of treatment of DKD with albuminuria•Finerenone has significantly reduced DKD progression and cardiovascular events compared with placebo in individuals with T2D and advanced DKD in two recent trials, the FIDELIO-DKD and the FIGARO-DKD.•Patients with type-2 diabetes can now benefit of a greater spectrum of therapeutical options to reduce their cardio-renal-metabolic risk.